B. Riley raised the firm’s price target on Perspective Therapeutics (CATX) to $12 from $9 and keeps a Buy rating on the shares. The firm says sequential positive updates from Perspective drive the higher price target It now sees an increased probabiliry of success for VMT-alpha-NET to deliver best-in-class efficacy and safety profile.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Optimistic Buy Rating for Perspective Therapeutics Driven by Strategic Developments and Promising Clinical Data
- Perspective Therapeutics commences recruitment for 212PbVMT-alpha-NET
- Perspective Therapeutics Updates on Radiopharmaceutical Advancements
- Perspective Therapeutics price target raised to $16 from $15 at RBC Capital
- Promising Clinical Trial Results and Safety Profile Drive Buy Rating for Perspective Therapeutics